Recursion Pharmaceuticals Inc Total Liabilities
Recursion Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Recursion Pharmaceuticals Inc (RXRX) has total liabilities worth $297.67 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See RXRX defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Recursion Pharmaceuticals Inc (2019–2025)
Total liabilities of Recursion Pharmaceuticals Inc from 2019 to 2025. This chart illustrates how Recursion Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check RXRX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Recursion Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Recursion Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Suzhou Secote Precision Electronic Co Ltd Class A
SHG:603283
|
China | CN¥2.74 Billion |
|
Ceconomy AG
XETRA:CEC
|
Germany | €9.64 Billion |
|
Grand Plastic Technology
TWO:3131
|
Taiwan | NT$12.17 Billion |
|
Dunelm Group plc
F:DFQ
|
Germany | €608.30 Million |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥5.67 Billion |
|
La Comer S.A.B. de C.V
MX:LACOMERUBC
|
Mexico | MX$8.02 Billion |
|
OFG Bancorp
NYSE:OFG
|
USA | $11.08 Billion |
|
Kinnevik Investment AB ser. B
ST:KINV-B
|
Sweden | Skr2.22 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Recursion Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Recursion Pharmaceuticals Inc total assets.
Liquidity & Leverage Metrics
Recursion Pharmaceuticals Inc Total Liabilities Ratios Explained
Recursion Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Recursion Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Recursion Pharmaceuticals Inc (2019–2025)
The table below shows the annual total liabilities of Recursion Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $343.26 Million | -17.05% |
| 2024-12-31 | $413.82 Million | +117.50% |
| 2023-12-31 | $190.26 Million | -11.70% |
| 2022-12-31 | $215.48 Million | +219.67% |
| 2021-12-31 | $67.41 Million | -86.65% |
| 2020-12-31 | $504.87 Million | +123.70% |
| 2019-12-31 | $225.70 Million | -- |
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenom… Read more